Table 3.
Coccidioidomycosis Presentations With Any Prescribed Immunomodulator in Autoimmune Patients
| Immunomodulator | PCM (n = 75) | CAV (n = 22) | ASYM (n = 22) | DCM (n = 19) | Total (n = 138) | P Value∗ | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||
| BRM | .06 | ||||||||||
| Yes | 17 | (22.7) | 3 | (13.6) | 3 | (13.6) | 9 | (47.4) | 32 | (23.2) | |
| No | 58 | (77.3) | 19 | (81.8) | 19 | (81.8) | 10 | (52.6) | 106 | (75.4) | |
| TNFI | .48 | ||||||||||
| Yes | 6 | (8.0) | 0 | (0.0) | 1 | (4.5) | 0 | (0.0) | 7 | (5.1) | |
| No | 69 | (92.0) | 22 | (100.0) | 21 | (95.5) | 19 | (100.0) | 131 | (94.9) | |
| Steroid | .27 | ||||||||||
| Yes | 24 | (32.0) | 4 | (18.2) | 9 | (40.9) | 8 | (42.1) | 45 | (32.6) | |
| No | 51 | (68.0) | 18 | (81.8) | 13 | (54.5) | 11 | (57.9) | 93 | (66.7) | |
| Steroid + BRMa | .15 | ||||||||||
| Yes | 34 | (45.3) | 6 | (27.3) | 11 | (50.0) | 12 | (63.2) | 63 | (45.7) | |
| No | 41 | (54.7) | 16 | (72.7) | 11 | (50.0) | 7 | (36.8) | 75 | (54.3) | |
| DMARD | .96 | ||||||||||
| Yes | 16 | (21.3) | 5 | (22.7) | 4 | (18.2) | 5 | (26.3) | 30 | (21.7) | |
| No | 59 | (77.3) | 17 | (77.3) | 18 | (72.7) | 14 | (73.7) | 108 | (76.1) | |
Abbreviations: ASYM, asymptomatic; BRM, biologic response modifier; CAV, chronic cavitary coccidioidomycosis; DCM, disseminated coccidioidomycosis; DMARD, disease-modifying antirheumatic drug; PCM, pulmonary coccidioidomycosis; TNFI, tumor necrosis factor–α inhibitor.
Either steroid or biologic response modifier identified in the electronic medical record, while those not counted had neither therapy.
Fisher exact test was used to evaluate categorical groups.